Tests imeroprubart in adults with a nerve disorder causing weakness and numbness
Tests imeroprubart against placebo in adults with chronic inflammatory demyelinating polyneuropathy.
Plain-language title generated from the registry record
Registry title: Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Key facts
- Where
- Boston, Canton, Carlsbad, Chapel Hill, Charlotte, Chicago, Detroit, Houston, Kansas City, Las Vegas, Maitland, Miami, Milwaukee, Mission Hills, New Haven, New York, Nicholasville, Orange, Ormond Beach, Parker, Philadelphia, Port Charlotte, Portland, Rancho Mirage, Rockledge, San Antonio, San Francisco, Tucson, Washington D.C., Worcester, and Yukon, United StatesSee the 33 sites
- Phase
- Phase 2
Where in United States
- BostonBoston, United StatesTaking people
- CantonCanton, United StatesNot yet recruiting
- CarlsbadCarlsbad, United StatesTaking people
- Chapel HillChapel Hill, United StatesNot yet recruiting
- CharlotteCharlotte, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- DetroitDetroit, United StatesTaking people
- HoustonHouston, United StatesTaking people
- Kansas CityKansas City, United StatesTaking people
- Las VegasLas Vegas, United StatesTaking people
- MaitlandMaitland, United StatesTaking people
- MiamiMiami, United StatesTaking people
- MilwaukeeMilwaukee, United StatesTaking people
- Mission HillsMission Hills, United StatesTaking people
- New HavenNew Haven, United StatesTaking people
- New YorkNew York, United StatesTaking people
- New YorkNew York, United StatesTaking people
- NicholasvilleNicholasville, United StatesTaking people
- OrangeOrange, United StatesTaking people
- Ormond BeachOrmond Beach, United StatesTaking people
- ParkerParker, United StatesTaking people
- PhiladelphiaPhiladelphia, United StatesTaking people
- Port CharlottePort Charlotte, United StatesTaking people
- PortlandPortland, United StatesTaking people
- Rancho MirageRancho Mirage, United StatesTaking people
- RockledgeRockledge, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- San FranciscoSan Francisco, United StatesTaking people
- TucsonTucson, United StatesTaking people
- Washington D.C.Washington D.C., United StatesTaking people
- Washington D.C.Washington D.C., United StatesTaking people
- WorcesterWorcester, United StatesTaking people
- YukonYukon, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Immunovant Sciences GmbH
- Trial code
- NCT07032662EU 2024-517614-14-00
- Record updated
- 30 September 2026
- Original description
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.Read full original descriptionShow less
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
Inclusion: Have met clinical diagnostic criteria for typical CIDP (including incomplete typical CIDP) or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of CIDP; Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN/PNS guideline on diagnosis and treatment of CIDP; Are currently on, and have been receiving chronic, stable doses of systemic corticosteroids (i.e., daily or every other day oral or pulse regimen), or immunoglobulin therapy (IVIg or SCIg) ± corticosteroid therapy (either low dose oral corticosteroids or pulse corticosteroids) for at least 3 months for the treatment of CIDP at the time of the Screening Visit; Additional inclusion criteria are defined in the protocol.
Exclusion: Have current or prior history of IgM paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies; Have distal, sensory, or focal CIDP, or have a diagnosis of autoimmune nodopathy per the EAN/PNS guideline on diagnosis and treatment of CIDP; Have polyneuropathy of causes other than CIDP including but not limited to:; Multifocal motor neuropathy; Hereditary demyelinating neuropathy; Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS); Lumbosacral radiculoplexus neuropathy; Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies; Drug- or toxin-induced; Have diabetes mellitus (DM) and meets any of the following criteria:; Does not have both typical CIDP and strong evidence of demyelination on nerve conduction study; In the opinion of the Investigator, there is evidence of poorly controlled DM preceding the diagnosis of CIDP; In the opinion of the Investigator, there is evidence of poorly controlled DM at screening; Have a history of myelopathy or evidence of central demyelination. Additional exclusion criteria are defined in the protocol.